Fredag 6 November | 01:56:24 Europe / Stockholm
Est. tid*
2027-02-11 08:00 Bokslutskommuniké 2026
2026-11-05 - Kvartalsrapport 2026-Q3
2026-08-13 - Kvartalsrapport 2026-Q2
2026-06-17 - Årsstämma
2026-05-18 - Kvartalsrapport 2026-Q1
2026-05-15 - X-dag ordinarie utdelning ACARIX 0.00 SEK
2026-02-12 - Bokslutskommuniké 2025
2025-11-06 - Kvartalsrapport 2025-Q3
2025-10-27 - Extra Bolagsstämma 2025
2025-08-21 - Kvartalsrapport 2025-Q2
2025-05-16 - X-dag ordinarie utdelning ACARIX 0.00 SEK
2025-05-15 - Årsstämma
2025-05-12 - Kvartalsrapport 2025-Q1
2025-02-13 - Bokslutskommuniké 2024
2024-11-07 - Kvartalsrapport 2024-Q3
2024-08-22 - Kvartalsrapport 2024-Q2
2024-05-15 - X-dag ordinarie utdelning ACARIX 0.00 SEK
2024-05-14 - Årsstämma
2024-05-14 - Kvartalsrapport 2024-Q1
2024-02-21 - Extra Bolagsstämma 2024
2024-02-15 - Bokslutskommuniké 2023
2023-11-09 - Kvartalsrapport 2023-Q3
2023-09-28 - Extra Bolagsstämma 2023
2023-08-31 - Kvartalsrapport 2023-Q2
2023-05-12 - X-dag ordinarie utdelning ACARIX 0.00 SEK
2023-05-11 - Årsstämma
2023-05-11 - Kvartalsrapport 2023-Q1
2023-02-16 - Bokslutskommuniké 2022
2022-12-09 - Extra Bolagsstämma 2022
2022-11-16 - Kvartalsrapport 2022-Q3
2022-08-25 - Kvartalsrapport 2022-Q2
2022-05-12 - X-dag ordinarie utdelning ACARIX 0.00 SEK
2022-05-11 - Årsstämma
2022-05-11 - Kvartalsrapport 2022-Q1
2022-02-17 - Bokslutskommuniké 2021
2021-11-23 - Extra Bolagsstämma 2021
2021-11-11 - Kvartalsrapport 2021-Q3
2021-08-19 - Kvartalsrapport 2021-Q2
2021-05-12 - X-dag ordinarie utdelning ACARIX 0.00 SEK
2021-05-11 - Årsstämma
2021-05-11 - Kvartalsrapport 2021-Q1
2021-02-18 - Bokslutskommuniké 2020
2020-11-12 - Kvartalsrapport 2020-Q3
2020-08-20 - Kvartalsrapport 2020-Q2
2020-08-11 - Extra Bolagsstämma 2020
2020-05-15 - X-dag ordinarie utdelning ACARIX 0.00 SEK
2020-05-14 - Årsstämma
2020-05-14 - Kvartalsrapport 2020-Q1
2020-02-20 - Bokslutskommuniké 2019
2019-11-14 - Kvartalsrapport 2019-Q3
2019-08-21 - Kvartalsrapport 2019-Q2
2019-08-16 - Extra Bolagsstämma 2019
2019-05-17 - X-dag ordinarie utdelning ACARIX 0.00 SEK
2019-05-16 - Årsstämma
2019-05-16 - Kvartalsrapport 2019-Q1
2019-02-20 - Bokslutskommuniké 2018
2018-11-14 - Kvartalsrapport 2018-Q3
2018-08-21 - Kvartalsrapport 2018-Q2
2018-05-24 - X-dag ordinarie utdelning ACARIX 0.00 SEK
2018-05-23 - Årsstämma
2018-05-23 - Kvartalsrapport 2018-Q1
2018-02-26 - Bokslutskommuniké 2017
2017-11-14 - Kvartalsrapport 2017-Q3
2017-08-24 - Kvartalsrapport 2017-Q2
2017-05-26 - X-dag ordinarie utdelning ACARIX 0.00 SEK
2017-05-24 - Årsstämma
2017-05-24 - Kvartalsrapport 2017-Q1
2017-02-23 - Bokslutskommuniké 2016
LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Acarix är ett diagnostikbolag. Bolaget har utvecklat en teknologi som möjliggör identifiering av kranskärlssjukdomar. Bolagets produkt är ett icke-invasivt test som sätts med en lapp på patienten för att analysera ljud från hjärtat. Verksamheten bedrivs främst inom den nordiska marknaden. Bolaget grundades år 2009 som en avknoppning från Coloplast. Huvudkontoret ligger i Malmö.

Analysera bolaget i Börsdata!

All ägardata du vill ha finns i Holdings!

Acarix Publishes Third Quarter 2026 Results

2026-11-05 08:00:00

Malmö, Sweden - Acarix, a leader in rapid AI and acoustics-based cardiac diagnostics, today reported its interim financial results for the third quarter of 2026. The quarter delivered the highest revenue in company history, driven by 215% U.S. revenue growth, a 149% increase in U.S. patch sales, and continued improvement in operating efficiency.

“The third quarter was a record for Acarix, delivering the highest quarterly revenue in our company’s history,” said Aamir Mahmood, President & CEO of Acarix. “Total revenue grew 22% to SEK 2,856 thousand, and revenue in our core U.S. market more than tripled, increasing 215% year-over-year. Just as important, U.S. patch sales rose 149%, a strong signal that clinicians are building CADScor® into their practice and that our recurring revenue base is growing. We achieved this while continuing to run a lean organization, reducing operating expenses by 9% and improving our net loss by 16%. For the first nine months, total revenue is up 45% and U.S. revenue is up 142%. Internationally, regulatory approvals in the United Arab Emirates and, following the quarter, Saudi Arabia open new markets that we will develop through local partners. As we close out 2026, we remain focused on increasing utilization across our installed base, growing our U.S. customer base, and expanding access to non-invasive frontline cardiac diagnostics.”

Third quarter 2026 compared to the same period in 2025:

  • Total revenue amounted to SEK 2,856 thousand (2,350), an increase of 22%.
  • In the U.S., revenue amounted to SEK 2,415 thousand (766) and an increase by 215%.
  • A total of 20 CADScor Systems (39) were delivered, representing a decrease of 49%. In the U.S. market, a total of 19 (22) systems were delivered, of which 18 (0) were sold and 1 (22) was delivered on consignment.
  • Sales of patches totaled 248 boxes (211), representing an increase of 17%. Each box contains 20 patches.
  • In the U.S. market, sales of patches totaled 194 boxes (78), representing an increase of 149%.
  • Gross margin amounted to 84% (85).
  • Total operating expenses amounted to SEK 9,927 thousand (10,934), representing a decrease of 9%.
  • The net loss amounted to SEK 7,738 thousand (9,211), representing a 16% improvement.
  • Cash flow from operating activities amounted to SEK -8,186 thousand (-7,161).
  • Earnings per share were SEK -0.01 (-0.01).

First nine months of 2026 compared to the same period in 2025:

  • Total revenue amounted to SEK 7,588 thousand (5,220), representing an increase of 45%.
  • Revenue in the U.S. market amounted to SEK 6,282 thousand (2,596), representing an increase of 142%.
  • A total of 78 CADScor Systems (78) were delivered, unchanged compared with the previous year.
  • In the U.S., 74 CADScor Systems (60) were delivered, an increase of 23%.
  • A total of 602 boxes of patches (508) were sold, an increase of 19%.
  • In the U.S., 456 boxes of patches (254) were sold, an increase of 80%.
  • Gross margin amounted to 83% (86).
  • Operating costs amounted to SEK 31,604 thousand (40,639), a decrease of 22%.
  • Net loss amounted to SEK -26,002 thousand (-36,535), a decrease of 29%.
  • Cash flow from operating activities was SEK -18,903 thousand (-31,493).
  • Earnings per share amounted to SEK –0.02 (–0.03).
  • Average number of shares amounted to 1,208,223,558 (1,123,320,142).

Link to the Acarix financial reports:
https://acarix.com/financial-reports-and-calendar/

For more information, contact:
Macie May
+1 405 517 5161
mmay@saxum.com